Estrogen replacement therapy by transdermal estradiol administration
| Autor: | John L. DeFazio, Peter Eggena, John K.H. Lu, David R. Meldrum, Jerome M. Hershman, Larry R. Laufer, Mohinder P. Sambhi, Howard L. Judd |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
medicine.medical_specialty
Injections Intradermal Estrone Random Allocation chemistry.chemical_compound Double-Blind Method Internal medicine medicine Humans Climacteric Transdermal Biologic marker Creatinine Estradiol business.industry Obstetrics and Gynecology Luteinizing Hormone medicine.disease Urinary calcium Menopause Hydroxyproline Endocrinology chemistry Calcium Female Follicle Stimulating Hormone Luteinizing hormone business Hormone |
| Zdroj: | American Journal of Obstetrics and Gynecology. 146:533-538 |
| ISSN: | 0002-9378 |
| DOI: | 10.1016/0002-9378(83)90796-2 |
| Popis: | To determine whether the nonoral administration of estradiol (E2) might provide physiologic replacement without alteration of hepatic function, 20 postmenopausal women were studied before and after 3 weeks of treatment with either E2-containing transdermal therapeutic systems or placebo. Twenty premenopausal women were also studied. With E2-containing systems, serum E2 and estrone levels were restored to the premenopausal range. Variable responses of the different biochemical and biologic markers of the actions of E2 were observed. The most sensitive marker was vaginal cytology, with the E2 dosage reverting the maturation index to premenopausal values. Hot flashes, measured objectively, were reduced in frequency but not abolished. Serum levels of follicle-stimulating hormone and luteinizing hormone were lowered but remained higher than the premenopausal range. No significant changes were noted in urinary calcium/creatinine and hydroxyproline/creatinine ratios, which were used as markers of bone resorption. With active systems, no significant changes were noted in the concentrations of the hepatic proteins renin substrate and thyroxine-binding globulin or in the binding capacities of cortisol-binding globulin and sex hormone-binding globulin. These results indicate that transdermal E2 administration may be used to provide estrogen replacement while exerting limited effects on hepatic function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|